CStone Pharmaceuticals Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
CStone Pharmaceuticals has been growing earnings at an average annual rate of 9.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 26.3% per year.
Key information
9.3%
Earnings growth rate
31.3%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 26.3% |
| Return on equity | -80.4% |
| Net Margin | -79.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified
May 12
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long
Apr 29Revenue & Expenses Breakdown
How CStone Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 464 | -367 | 382 | 528 |
| 30 Sep 23 | 472 | -559 | 449 | 531 |
| 30 Jun 23 | 481 | -750 | 516 | 534 |
| 31 Mar 23 | 481 | -827 | 546 | 574 |
| 31 Dec 22 | 481 | -903 | 576 | 614 |
| 30 Sep 22 | 454 | -1,205 | 616 | 836 |
| 30 Jun 22 | 426 | -1,508 | 655 | 1,059 |
| 31 Mar 22 | 335 | -1,714 | 658 | 1,182 |
| 31 Dec 21 | 244 | -1,920 | 661 | 1,305 |
| 30 Sep 21 | 681 | -1,622 | 622 | 1,339 |
| 30 Jun 21 | 1,118 | -1,324 | 583 | 1,373 |
| 31 Mar 21 | 1,079 | -1,272 | 534 | 1,389 |
| 31 Dec 20 | 1,039 | -1,221 | 485 | 1,405 |
| 30 Sep 20 | 519 | -1,482 | 424 | 1,480 |
| 30 Jun 20 | -2 | -1,744 | 363 | 1,556 |
| 31 Mar 20 | -1 | -1,906 | 352 | 1,476 |
| 31 Dec 19 | 0 | -2,069 | 341 | 1,396 |
| 30 Sep 19 | 11 | -1,688 | 327 | 1,040 |
| 30 Jun 19 | 12 | -1,246 | 322 | 725 |
| 31 Mar 19 | 12 | -858 | 256 | 788 |
| 31 Dec 18 | 13 | -470 | 191 | 850 |
| 30 Sep 18 | 13 | -336 | 130 | 747 |
| 31 Dec 17 | 10 | -107 | 39 | 213 |
Quality Earnings: 2616 is currently unprofitable.
Growing Profit Margin: 2616 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2616 is unprofitable, but has reduced losses over the past 5 years at a rate of 9.3% per year.
Accelerating Growth: Unable to compare 2616's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2616 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.7%).
Return on Equity
High ROE: 2616 has a negative Return on Equity (-80.39%), as it is currently unprofitable.